201 related articles for article (PubMed ID: 28661474)
21. Progress in the research of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer.
Xian J; Cheng Y; Qin X; Cao Y; Luo Y; Cao Y
J Cell Mol Med; 2020 Jul; 24(13):7451-7459. PubMed ID: 32501652
[TBL] [Abstract][Full Text] [Related]
22. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
[TBL] [Abstract][Full Text] [Related]
23. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
24. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
25. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
26. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
27. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
28. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
29. Distinct Classes of Flavonoids and Epigallocatechin Gallate, Polyphenol Affects an Oncogenic Mutant p53 Protein, Cell Growth and Invasion in a TNBC Breast Cancer Cell Line.
Kollareddy M; Martinez LA
Cells; 2021 Apr; 10(4):. PubMed ID: 33918387
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
Qiao Y; Wang B; Yan Y; Niu L
Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
[TBL] [Abstract][Full Text] [Related]
31. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
32. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
33. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
34. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
Udden SM; Morita-Fujimura Y; Satake M; Ikawa S
Cell Signal; 2014 Feb; 26(2):444-52. PubMed ID: 24177958
[TBL] [Abstract][Full Text] [Related]
35. Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Furlan A; Stagni V; Hussain A; Richelme S; Conti F; Prodosmo A; Destro A; Roncalli M; Barilà D; Maina F
Cell Death Differ; 2011 Oct; 18(10):1608-16. PubMed ID: 21455220
[TBL] [Abstract][Full Text] [Related]
36. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
[TBL] [Abstract][Full Text] [Related]
37. Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress.
Lee JH; Jeong MW; Kim W; Choi YH; Kim KT
J Biol Chem; 2008 Jul; 283(28):19826-35. PubMed ID: 18490454
[TBL] [Abstract][Full Text] [Related]
38. c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
Whang YE; Tran C; Henderson C; Syljuasen RG; Rozengurt N; McBride WH; Sawyers CL
Proc Natl Acad Sci U S A; 2000 May; 97(10):5486-91. PubMed ID: 10805805
[TBL] [Abstract][Full Text] [Related]
39. IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Zuo S; Liu C; Wang J; Wang F; Xu W; Cui S; Yuan L; Chen X; Fan W; Cui M; Song G
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1045-55. PubMed ID: 22392074
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]